134 related articles for article (PubMed ID: 10353326)
21. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
[TBL] [Abstract][Full Text] [Related]
23. A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases.
Nakashima J; Sumitomo M; Miyajima A; Jitsukawa S; Murai M
Urol Int; 1997; 58(4):236-8. PubMed ID: 9253125
[TBL] [Abstract][Full Text] [Related]
24. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
25. Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis.
Akimoto S; Furuya Y; Akakura K; Ito H
Endocr J; 1998 Feb; 45(1):97-104. PubMed ID: 9625452
[TBL] [Abstract][Full Text] [Related]
26. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
Kobayashi Y; Ochi M; Tokue A
Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
[TBL] [Abstract][Full Text] [Related]
27. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract][Full Text] [Related]
28. Biochemical markers of bone formation in the study of postmenopausal osteoporosis.
Dominguez Cabrera C; Sosa Henríquez M; Traba ML; Alvarez Villafañe E; de la Piedra C
Osteoporos Int; 1998; 8(2):147-51. PubMed ID: 9666938
[TBL] [Abstract][Full Text] [Related]
29. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.
Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G
Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961
[TBL] [Abstract][Full Text] [Related]
30. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer?
Perachino M; Di Ciolo L; Barbetti V; Puppo P
Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025
[TBL] [Abstract][Full Text] [Related]
31. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
[TBL] [Abstract][Full Text] [Related]
32. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases.
Cooper EH; Forbes MA; Hancock AK; Parker D; Laurence V
Biomed Pharmacother; 1992; 46(1):31-6. PubMed ID: 1421033
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate.
Wolff JM; Ittel T; Borchers H; Brauers A; Jakse G
Urol Int; 1998 Oct; 61(1):12-6. PubMed ID: 9792976
[TBL] [Abstract][Full Text] [Related]
34. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.
Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J
Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961
[TBL] [Abstract][Full Text] [Related]
35. [Bone scintigraphy for diagnosis of bone metastasis in patients with prostatic cancer].
Nakashima J
Nihon Rinsho; 2002 Dec; 60 Suppl 11():135-9. PubMed ID: 12599559
[No Abstract] [Full Text] [Related]
36. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer.
Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E
Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666
[TBL] [Abstract][Full Text] [Related]
38. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram.
Stokkel M; Zwinderman A; Zwartendijk J; Pauwels E; van Eck-Smit B
Eur J Nucl Med; 1997 Oct; 24(10):1215-20. PubMed ID: 9323261
[TBL] [Abstract][Full Text] [Related]
39. [Serum alkaline phosphatase flare in prostate cancer accompanied by bone metastases and treated with hormonal therapy. TEKK Study Group].
Taue R; Kanayama H; Kagawa S
Hinyokika Kiyo; 1999 Oct; 45(10):681-5. PubMed ID: 10586358
[TBL] [Abstract][Full Text] [Related]
40. Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase.
Curatolo C; Ludovico GM; Correale M; Pagliarulo A; Abbate I; Cirrillo Marucco E; Barletta A
Eur Urol; 1992; 21 Suppl 1():105-7. PubMed ID: 1385127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]